Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Gains from Investment Securities (2016 - 2025)

Anaptysbio (ANAB) has disclosed Gains from Investment Securities for 9 consecutive years, with $6.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Investment Securities changed N/A year-over-year to $6.9 million, compared with a TTM value of $6.9 million through Dec 2025, down 8.08%, and an annual FY2025 reading of $6.9 million, down 8.08% over the prior year.
  • Gains from Investment Securities was $6.9 million for Q4 2025 at Anaptysbio, up from -$61.6 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $20.7 million in Q2 2021 and bottomed at -$61.6 million in Q3 2025.
  • Average Gains from Investment Securities over 5 years is -$3.9 million, with a median of $500.0 recorded in 2021.
  • The sharpest move saw Gains from Investment Securities soared 151.83% in 2022, then crashed 222.41% in 2023.
  • Year by year, Gains from Investment Securities stood at -$1.4 million in 2021, then soared by 839.45% to $10.7 million in 2022, then rose by 22.41% to $13.1 million in 2023, then crashed by 42.83% to $7.5 million in 2024, then decreased by 8.08% to $6.9 million in 2025.
  • Business Quant data shows Gains from Investment Securities for ANAB at $6.9 million in Q4 2025, -$61.6 million in Q3 2025, and $1.5 million in Q1 2025.